Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant versus amiodarone for recent-onset atrial fibrillation
NL-OMON33298Phase 3Active, not recruiting
- Sponsor
- IQVIA
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Vernakalant injection with Amiodarone injection (2 arms). Primary endpoints: Conversion of atrial fibrillation to sinus rhythm within 90 minutes and Symptom relief at 90 minutes. Started Sep 2009; status: active, not recruiting.
02
Drugs
vernakalantamiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON33298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33298.